Sacramento, CANCT07513285Now EnrollingIRB Ready

Clostridium Difficile Infection Recurrence Clinical Trial in Sacramento, CA

Access cutting-edge clostridium difficile infection recurrence treatment through this phase 2 clinical trial at a research site in Sacramento. Study-provided care at no cost to qualified participants.

Sponsored by Acurx Pharmaceuticals Inc.

Quick Self-Assessment

See if you qualify for this Sacramento location

Preparing your pre-screening questions…

Expert Care in Sacramento

Access clostridium difficile infection recurrence specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related clostridium difficile infection recurrence treatment provided free

Apply for This Sacramento Location

Check if you qualify for this clostridium difficile infection recurrence clinical trial in Sacramento, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Sacramento

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Sacramento site if eligible
  4. 4Begin participation

About This Clostridium Difficile Infection Recurrence Study in Sacramento

Single-arm trial to evaluate the safety and efficacy of ACX-362E \[ibezapolstat\] in patients with recurrent C. difficile infection (CDI).

Sponsor: Acurx Pharmaceuticals Inc.

Who Can Participate

Inclusion Criteria

Confirmed diagnosis of CDI as defined by 1) the presence of diarrhea, defined as passage of ≥ 3 UBMs within 24 hours before study Day 1, AND 2) a stool test result positive for the presence of C. difficile free toxins
Three or more CDI episodes in the past 12 months, including the current episode, with each episode defined as ≥ 3 unformed stools in 24 hours associated with positive C. difficile toxin test.
At least 1 of the protocol-qualifying prior CDI episodes, not including the current episode, has been treated with oral vancomycin or with fidaxomicin

Exclusion Criteria

Severe, complicated, or life-threatening fulminant CDI with evidence of hypotension (systolic blood pressure \< 90 mmHg), septic shock, peritoneal signs or ileus, or toxic megacolon
Received more than 24 hours of dosing with antibiotics for the current CDI episode:
Received a live biotherapeutic product (LBP) (Rebyota® or Vowst™) within the past 12 weeks
Received or current use of anti-C. difficile antibodies, eg, IV immunoglobulin \[IVIG\], bezlotoxumab
Active inflammatory bowel disease (Crohn's disease, ulcerative colitis) with chronic diarrhea within 12 weeks before Baseline, or with a history of symptoms \> 12 weeks before Baseline without evidence of mucosal healing on colonoscopy within the past year.
Active irritable bowel syndrome with chronic diarrhea in the past 12 weeks.
Active gastroenteritis because of Salmonella, Shigella, Escherichia coli 0157H7, Yersinia or Campylobacter, other bacteria, a parasite, or a virus within the past 2 weeks
Major GI surgery (eg, significant bowel resection) within 3 months of enrollment (does not include appendectomy or cholecystectomy).
Known current history of a severely compromised immune system

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Sacramento?

Yes, this clinical trial (NCT07513285) has an active research site in Sacramento, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Clostridium Difficile Infection Recurrence Treatment Options in Sacramento, CA

If you're searching for clostridium difficile infection recurrence treatment options in Sacramento, CA, this clinical trial (NCT07513285) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Sacramento research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced clostridium difficile infection recurrence specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all clostridium difficile infection recurrence clinical trials near you to find additional studies recruiting in your area.

More Clostridioides Difficile Infection Trials in Sacramento, CA

See all clostridioides difficile infection clinical trials recruiting in Sacramento — not just this study.

Browse Clostridioides Difficile Infection Trials in Sacramento →

Browse More Trials by Condition

Clostridioides Difficile Infection TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Sacramento?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Sacramento, CA